# Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

> **NCT02768558** · PHASE3 · TERMINATED · sponsor: **RTOG Foundation, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **RADIATION:** Radiation Therapy (RT)
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Nivolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02768558
- **Lead sponsor:** RTOG Foundation, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-17
- **Primary completion:** 2019-01-23
- **Final completion:** 2019-01-23
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Another treatment found efficacious
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768558, "Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02768558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*